Vimarsana
Biggest News Aggregation in the World

J Mark Madison News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from J Mark Madison. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In J Mark Madison Today - Breaking & Trending Today

UWO '70s superhero Augmento was more than just a comic strip - Vimarsana News

UWO '70s superhero Augmento was more than just a comic strip

Augmento, UW Oshkosh’s first fictional superhero, was featured in a comic strip of the same name in the Advance-Titan created by UWO alumni in the ’70s. The series, which started as a hobby for three friends, became a form of edgy rebellion, creativity and expression for opinions on people and things around campus.  Meet the...

Gefapixant Leads to Modest Improvements in Cough - Vimarsana News

Gefapixant Leads to Modest Improvements in Cough

MONDAY, Sept. 11, 2023 (HealthDay News) -- For adults with refractory or unexplained chronic cough, gefapixant leads to modest improvement in cough frequency, severity, and quality of life, according to a review published online Sept. 11 in the Journal of the American Medical Association to coincide with the European Respiratory Society International Congress 2023, held

Gefapixant Leads to Modest Improvements in Cough - Vimarsana News

Gefapixant Leads to Modest Improvements in Cough

Modest improvement seen in cough frequency, severity, and specific quality of life, but increase seen in treatment-, taste-related adverse events.

Source: empr.com
Gefapixant Leads to Modest Improvements in Cough - Vimarsana News

Gefapixant Leads to Modest Improvements in Cough

MONDAY, Sept. 11, 2023 (HealthDay News) -- For adults with refractory or unexplained chronic cough, gefapixant leads to modest improvement in cough frequency, severity, and quality of life, according to

Chronic Cough Drug Shows Some Benefit, but Taste-Related Events an Issue - Vimarsana News

Chronic Cough Drug Shows Some Benefit, but Taste-Related Events an Issue

Meta-analysis found mixed results for a drug that's about to go before an FDA panel